VIA
MDGL icon

Virtus Investment Advisers’s Madrigal Pharmaceuticals MDGL Stock Holding History

Virtus Investment Advisers’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.3M Buy
2,419
+943
+64% +$483K 0.3% 151
2026
Q1 		$773K Buy
1,476
+282
+24% +$135K 0.21% 166
2025
Q4 		$695K Sell
1,194
-301
-20% -$154K 0.19% 168
2025
Q3 		$686K Hold
1,495
– – 0.2% 172
2025
Q2 		$452K Buy
1,495
+307
+26% +$91.5K 0.15% 194
2025
Q1 		$394K Buy
+1,188
New +$390K 0.11% 211

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Virtus Investment Advisers's MDGL Position: Q2 2026 in Review

Virtus Investment Advisers increased its Madrigal Pharmaceuticals (MDGL) stake by 64% in Q2 2026, buying an estimated $483K and bringing the position to 2,419 shares worth $1.3M. The position accounts for 0.3% of the portfolio, ranked #151.

Virtus Investment Advisers first reported a position in MDGL in Q1 2025 and has held it in 6 quarters since. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Virtus Investment Advisers held 2,419 shares of Madrigal Pharmaceuticals worth $1.3M as of Q2 2026.
  • Virtus Investment Advisers bought 943 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $483K.
  • Madrigal Pharmaceuticals made up 0.3% of Virtus Investment Advisers's portfolio in Q2 2026, its #151 holding.
  • Virtus Investment Advisers first reported a position in Madrigal Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.